Can AI be a Pathologist's second opinion?
NCT ID NCT07741058
First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time
Summary
This trial tests whether an AI tool called ENLIGHT can help pathologists more accurately and quickly distinguish between certain lung and kidney cancer subtypes. Pathologists will review digitized slides under three conditions: without AI, with AI as a double-check after their own diagnosis, and with AI as a first-look before they start. The study aims to see if AI assistance improves diagnostic accuracy, speed, and confidence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AI-assisted diagnostic tool (ENLIGHT) used as a double-check or first-look during pathology review
- What this could lead to
- If AI assistance improves diagnostic accuracy and speed, it could become a standard tool to help pathologists make more precise cancer subtype diagnoses, potentially leading to better treatment decisions.
- What could go wrong
- This is a small early-stage study with only 25 participants, so results may not apply broadly. AI might not consistently improve accuracy or could introduce new errors, and its benefit may vary depending on how it's used.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Harvard Medical School,
Boston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare
- Can simple positive activities boost Well-Being in cancer care?